Michael Klein

Cooley advised Kim Kardashian, an American media personality, socialite and businesswoman, on SKIMS’ acquisition of SKKN by Kim, a beauty, skincare, and fragrance brand she founded, including the 20% stake held by Coty.

Cooley advised H1, a global healthcare data technology company, on its acquisition of Ribbon Health.

The Chapter 11 plan of PhaseBio Pharmaceuticals, a long-standing Cooley life sciences client, has gone effective following the court’s confirmation of the Chapter 11 plan on June 26, 2024. The plan provides for a global settlement with the official committee of unsecured creditors and a settlement with PhaseBio’s former co-development partner. The Chapter 11 bankruptcy case in the US Bankruptcy Court for the District of Delaware was handled by a multioffice, cross-disciplinary Cooley team.

Cooley advised long-time biotech client, Gamida Cell Ltd., and its wholly-owned subsidiary, Gamida Cell Inc. (collectively, the “Company”), in the Company’s global restructuring through a novel use of debt arrangement proceedings in Israel combined with Chapter 15 and 11 proceedings in the United States. 

Cooley advised Yardi Systems, a large software corporation with offices worldwide, in connection with WeWork’s emergence from Chapter 11 and completion of WeWork’s global operational and financial restructuring.